[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"corneal-neovascularization\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:corneal-neovascularization":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100422948","phase-2-corneal-crosslinking-for-treatment-of-corneal-neovascularization-100422948",false,"NCT04787471","Corneal Crosslinking for Treatment of Corneal Neovascularization","Randomized Comparison of Standard vs. Accelerated Corneal Crosslinking for Treatment of Corneal Neovascularization With or Without Concomitant Inflammation and\u002For Infection","Inclusion Criteria:\n\n* 18 years of age or older\n* With active inflammation or infection causing vascularization and possibly melting of the cornea, or vessels extending into the cornea causing lipid deposition, or vascularization that could significantly increase the risk of rejection of a current or planned corneal transplant, or vessels that continue to extend into the cornea despite topical treatment with corticosteroids.\n* Signed written informed consent.\n\nExclusion Criteria:\n\n* Known sensitivity to treatment medications\n* Current condition that in the investigator's opinion could compromise safety or data integrity.\n* Pregnancy (including plan to become pregnant) or lactation during the course of the study","ALL","18 Years",{"count":19,"type":20},138,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE2","PHASE3","The study objective is to assess safety and efficacy of photo-activation of riboflavin for treatment of corneal neovascularization with or without concomitant inflammation and\u002For infection.",[27],"Corneal Neovascularization","RECRUITING","2026-09-14",{"date":31,"type":32},"2026-09-17","ACTUAL",{"date":34,"type":32},"2021-05-03",{"date":36,"type":20},"2029-09-15",{"name":38,"class":39},"Price Vision Group","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":40},"100618289","phase-1-clinical-study-of-intrastromal-anti-vegf-injection-for-corneal-neovascularization-100618289","NCT07329686","Clinical Study of Intrastromal Anti-VEGF Injection for Corneal Neovascularization.","Inclusion Criteria:\n\n* Diagnosis: Patients who meet the diagnostic criteria for Herpes Simplex Virus (HSV) keratitis with neovascularization.\n* Age: Adults aged 18 years or older.\n* Previous Treatment: Patients who have not undergone other anti-VEGF treatments or corneal surgeries.\n* Informed Consent: Patients who are capable of understanding and signing an informed consent form, agreeing to participate in the entire study process and to follow the study's follow-up schedule and treatment plan.\n* Other: Additional criteria as deemed necessary by the investigator.\n\nExclusion Criteria:\n\n* Risk of Corneal Perforation: Patients at risk of corneal perforation.\n* Severe Ocular Surface Dryness: Patients with severe dry eye syndrome.\n* Systemic Diseases: Patients with systemic diseases that may affect the nervous or immune systems, such as diabetes, rheumatoid arthritis, autoimmune diseases, etc.\n* Recent Use of Systemic Immunosuppressants: Patients who have recently used systemic immunosuppressive agents.\n* Poor Compliance: Patients who are unable to follow up on time or adhere to the treatment plan.\n* Pregnancy or Lactation: Pregnant or nursing women, as their physiological state may affect study outcomes.\n* Allergy History: Patients with a history of allergies to the study medication or related components.\n* Other Reasons: Patients deemed by the investigator to have other reasons making them unsuitable for participation in the trial.",{"count":48,"type":20},100,[50,23],"PHASE1","Corneal stromal injection is an emerging local drug delivery method, characterized by strong targeting, high drug concentration, and prolonged duration of action. It has been preliminarily applied in the treatment of fungal keratitis and neurotrophic corneal diseases. This study aims to investigate the safety and efficacy of anti-VEGF drugs delivered via corneal stromal injection in neovascularization caused by HSK (Herpes Simplex Keratitis). The study has clear medical significance and technical feasibility, and it is expected to promote innovation in the treatment paradigm for corneal neovascularization.",[53,27],"Herpes Simplex Keratitis",[53,55],"corneal neovascularization","2026-01-06",{"date":58,"type":32},"2026-01-09",{"date":60,"type":32},"2025-10-01",{"date":62,"type":20},"2026-10",{"name":64,"class":65},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER"]